MET and non-small cell lung carcinoma: On the basis of these results, the phase II LUMINOSITY trial (NCT03539536) was expanded on the selected group (c-Met-overexpressing non-squamous EGFR-wild-type NSCLC) for further evaluation of Teliso-V’s efficacy [51].